Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Solid Tumors Harboring NTRK Fusion: early-phase trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Solid Tumors Harboring NTRK Fusion: 3 US clinical trials tracked, none currently recruiting.
Solid Tumors Harboring NTRK Fusion is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Bayer, running 3 of these trials.
Enrollment posture brief
Registry condition solid-tumors-harboring-ntrk-fusion
OPEN 0 | RECR 0% | LATE 0 | EARLY 3 | RANK #5209 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Solid Tumors Harboring NTRK Fusion has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Solid Tumors Harboring NTRK Fusion on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Solid Tumors Harboring NTRK Fusion is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children
Bayer
NCT02637687
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
Bayer
NCT02576431
Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants
Bayer
NCT04771390
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Solid Tumors Harboring NTRK Fusion records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Solid Tumors Harboring NTRK Fusion trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Solid Tumors Harboring NTRK Fusion page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Solid Tumors Harboring NTRK Fusion trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Bayer sponsors the most Solid Tumors Harboring NTRK Fusion trials on record, review their full trial history before evaluating a specific study. See Bayer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Solid Tumors Harboring NTRK Fusion condition card totals 3 registered trials; most-linked intervention Selitrectinib (BAY2731954) Oral suspension; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.